Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Fabi

Showing results (141-150 of 265) with videos related to

Pageof 27
Sort By:
Tumori|October 10, 2014
Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trialGiuseppina Sanna, Alessandra Fabi, Diana Crivellari, et al.
Plos One|February 14, 2008
Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomasValentina Folgiero, Paolo Avetrani, Giulia Bon, et al.
Cancer Treatment Reviews|December 20, 2023
Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs)Arianna Dri, Grazia Arpino, Giampaolo Bianchini, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 20, 2011
Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating centerAlessandra Fabi, Alessandra Felici, Giulio Metro, et al.
Environmental Pollution (Barking, Essex : 1987)|May 13, 2025
Bisphenol A drives nuclear factor-kappa B signaling activation and enhanced motility in non-transformed breast cellsAnna Citarella, Zein Mersini Besharat, Lucia Coppola, et al.
Clinical Breast Cancer|June 26, 2020
p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational StudyAlessandra Fabi, Marcella Mottolese, Anna Di Benedetto, et al.
Frontiers in Oncology|November 17, 2022
Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practiceGiuseppe Buono, Grazia Arpino, Lucia Del Mastro, et al.
JCO Oncology Practice|October 9, 2025
Comprehensive Diagnostic and Therapeutic Approaches for Estrogen Receptor-Low Breast Cancer: A Multidisciplinary Perspective From Oncologists and PathologistsPaola Zagami, Andrea Botticelli, Isabella Castellano, et al.
Cancer Investigation|April 25, 2007
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patientsPaolo Carlini, Andrea Michelotti, Gianluigi Ferretti, et al.
Breast (Edinburgh, Scotland)|July 11, 2016
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survivalLuisa Carbognin, Isabella Sperduti, Mariangela Ciccarese, et al.
Pageof 27

Showing results (141-150 of 265) with videos related to

Sort By:
Pageof 27
Tumori|October 10, 2014
Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trialGiuseppina Sanna, Alessandra Fabi, Diana Crivellari, et al.
Plos One|February 14, 2008
Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomasValentina Folgiero, Paolo Avetrani, Giulia Bon, et al.
Cancer Treatment Reviews|December 20, 2023
Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs)Arianna Dri, Grazia Arpino, Giampaolo Bianchini, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 20, 2011
Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating centerAlessandra Fabi, Alessandra Felici, Giulio Metro, et al.
Environmental Pollution (Barking, Essex : 1987)|May 13, 2025
Bisphenol A drives nuclear factor-kappa B signaling activation and enhanced motility in non-transformed breast cellsAnna Citarella, Zein Mersini Besharat, Lucia Coppola, et al.
Clinical Breast Cancer|June 26, 2020
p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational StudyAlessandra Fabi, Marcella Mottolese, Anna Di Benedetto, et al.
Frontiers in Oncology|November 17, 2022
Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practiceGiuseppe Buono, Grazia Arpino, Lucia Del Mastro, et al.
JCO Oncology Practice|October 9, 2025
Comprehensive Diagnostic and Therapeutic Approaches for Estrogen Receptor-Low Breast Cancer: A Multidisciplinary Perspective From Oncologists and PathologistsPaola Zagami, Andrea Botticelli, Isabella Castellano, et al.
Cancer Investigation|April 25, 2007
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patientsPaolo Carlini, Andrea Michelotti, Gianluigi Ferretti, et al.
Breast (Edinburgh, Scotland)|July 11, 2016
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survivalLuisa Carbognin, Isabella Sperduti, Mariangela Ciccarese, et al.
Pageof 27